17 filings
8-K
NRBO
NeuroBo Pharmaceuticals Inc
30 Dec 19
Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals
9:04pm
8-K
NRBO
NeuroBo Pharmaceuticals Inc
30 Dec 19
Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals
11:24am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
6 Dec 19
Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals
4:03pm
8-K
NRBO
NeuroBo Pharmaceuticals Inc
30 Oct 19
Entry into a Material Definitive Agreement
12:00am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
8 Oct 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
8-K
o62f6di3xy
3 Oct 19
Departure of Directors or Certain Officers
4:06pm
8-K
def3a7hyxql
24 Sep 19
Other Events
4:17pm
8-K
97dtcj
15 Aug 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:02am
8-K
dp6jsjm ut
9 Aug 19
Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
8:16am
8-K
dwhsx1s55 tzx
25 Jul 19
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company
6:38am
8-K
dri0e yu5n
26 Jun 19
Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial
8:09am
8-K
fovjtyby 1u
13 May 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
8-K
dieiceikluid4
22 Mar 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:00am
8-K
6rpv x49p
15 Mar 19
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results
8:05am
8-K
6bxuuqp
5 Mar 19
Departure of Directors or Certain Officers
4:05pm
8-K
54x0izqe
31 Jan 19
Termination of a Material Definitive Agreement
4:15pm
8-K
5qqhvpmej
7 Jan 19
Regulation FD Disclosure
8:07am
- Prev
- 1
- Next